Case Report: PD-1/CTLA-4 dual checkpoint blockade(QL1706) in advanced pulmonary squamous cell carcinoma complicated by multidrug-resistant tuberculosis after multiple lines of immunotherapy
{{output}}
Immune checkpoint inhibitors (ICIs) are standard care for advanced non-small cell lung cancer (NSCLC), yet patients with active tuberculosis (TB) are consistently excluded from clinical trials. Furthermore, data guiding the use of dual PD-1/CTLA-4 blockade in ... ...
